Press Releases
Brinks Gilson & Lione Litigators Ralph Gabric, Laura Lydigsen Present at ACI Paragraph IV Disputes Conference
April 21, 2017

CHICAGO—Ralph J. Gabric and Laura A. Lydigsen, shareholders and patent litigators at intellectual property law firm Brinks Gilson & Lione, will be featured presenters at the 11th Annual ACI Paragraph IV Disputes Conference on April 25, 2017, at the Conrad New York.

Ralph Gabric will moderate the session “The PTAB Live: Thoughts on Practice, Procedure, IPRs and More in the World of Pharmaceutical Patent Validity Challenges,” in which a panel of administrative patent judges from the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) will discuss the protocols and art of appearance for Hatch-Waxman petitioners in inter partes reviews before this administrative body. 

Gabric, who co-chairs Brinks’ litigation practice group, focuses his practice on protecting and defending innovations related to diverse technologies. During his 28 years as a patent attorney, he has represented generic pharmaceutical companies in Hatch-Waxman litigation, appeared as lead counsel in numerous cases involving drug products, and assisted clients with regulatory and pre-litigation strategies. Gabric is a frequent speaker and author on current topics in patent law.

Laura Lydigsen will be a speaker on the panel “PTAB Pharmaceutical Patent Invalidity Round-Up: Update on Wins, Losses and Appeals.” The panelists will offer a survey of notable wins and losses at the PTAB, examine statistics for types of challenges brought and types of patents challenged, analyze Federal Circuit decisions relative to pharmaceutical patent challenges brought at the PTAB, explore the implications of the PTAB’s rules package and the status of pending cases impacting new rules, and give an update on the activity of reverse patent trolls and the status of pending patent reform legislation.

Lydigsen chairs Brinks’ appellate practice group. Her practice includes intellectual property litigation at both the district court and appellate levels, with a focus on pharmaceuticals, biotechnology, and medical devices. Lydigsen has extensive experience in representing generic pharmaceutical companies in Hatch-Waxman litigation, and has written briefs in dozens of Federal Circuit appeals, including complex multi-patent appeals stemming from PTAB decisions in post-grant proceedings.

Brinks Gilson & Lione is a Supporting Sponsor of the 11th Annual Paragraph IV Disputes Conference, a forum for brand and generic pharmaceutical companies to get the most up-to-date information on the latest developments in Paragraph IV litigation, from pre-suit considerations to case filings to final adjudication. More information is at

Brinks Gilson & Lione

Celebrating its centennial year in 2017, Brinks Gilson & Lione is one of the largest intellectual property law firms in the US, and helps clients around the world to protect and enforce their intellectual property rights. Brinks Gilson & Lione’s more than 140 lawyers, patent agents and scientific advisors assist clients in all aspects of patent, trademark, unfair competition, trade secret, and copyright law. Brinks attorneys provide informed counsel with respect to innovations in a range of complex and valuable technologies, including pharmaceuticals, chemicals, bioengineering, industrial manufacturing, electronics and software, and medical devices. More information is at

Forward Thinkers